SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is currently a focal point due to intense speculation surrounding its reported all-cash revised bid for Warner Bros. Discovery, a move that comes amidst a contentious bidding war and legal challenges from a rival suitor. The community is sharply divided, with bulls anticipating a significant run-up and potential short squeeze ahead of upcoming earnings, while cautious investors highlight potential regulatory hurdles and the stock's recent volatility. This acquisition drama underscores the ongoing strategic battle for content and market share within the streaming industry.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is highly active after a significant downgrade and "Sell" rating from Goldman Sachs spurred widespread discussion. The community is sharply divided, with many seeing the move as institutional manipulation designed to depress the stock for cheaper accumulation, while others underscore ongoing concerns regarding the company's profit margins and management execution. As a critical infrastructure provider in the booming AI sector, investors are closely watching how the company navigates these challenges.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan is trending following its recent financial report, which included a notable impact from acquiring a new credit card portfolio. The community is actively debating this development, alongside significant concerns about a proposed cap on credit card interest rates that the bank's leadership has publicly stated would necessitate major business adjustments. Despite an initial market reaction, many investors are discussing whether this presents a "buy the dip" opportunity for the financial institution.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending due to robust revenue estimates for Briumvi through 2026, fueled by strong demand and positive updates from investor presentations. The community is actively discussing the company's significant growth potential and its best-in-class drug profile, alongside ongoing frustration over perceived stock manipulation and the lack of a major price breakout. With competing therapies facing setbacks, many anticipate substantial long-term value appreciation, while some remain skeptical given past stock performance.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe is trending amid a flurry of analyst downgrades, citing intensified AI competition and its potential impact on the company's growth and valuation, exacerbated by new competitive offerings like Apple's creative suite. Community sentiment is sharply divided, with many fearing AI will render Adobe's offerings obsolete, while others view the stock as a deeply undervalued 'cash cow' with impeccable financials. This debate is set against a broader market re-evaluation where software stocks are facing pressure to effectively monetize AI.

Ambitions Enterprise Management Co. LLC operates as a travel agency. It provides event planning and management services. The firm also offers transportation, accommodations, meals, and guided tours or activities under convenient packages. The company was founded on October 26, 2023 and is headquartered in Dubai, United Arab Emirates.

Ambitions Enterprise Management Co LLC - Ordinary Shares - Class A

Ambitions Enterprise Management Co LLC

Ambitions Enterprise Management Co. (AHMA) is actively trending due to a significant surge in both price and trading volume. This rapid movement is fueling community discussions about its notably low float, leading to speculation around a potential short squeeze, with many drawing parallels to past parabolic runners despite the absence of clear fundamental news and some concerns about potential share offerings.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

BMNR is trending due to an imminent shareholder vote on a significant increase in authorized shares, sparking intense community debate over potential dilution versus enabling aggressive Ethereum acquisition and long-term growth. Many investors are weighing trust in management's vision for ETH tokenization and staking against concerns about the impact on current share value, especially given recent Ethereum price fluctuations.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending with significant community speculation ahead of its presentation at the J.P. Morgan Healthcare Conference, following a recent analyst upgrade and an 8-K filing hinting at new partnerships and strategic de-risking. Investors are closely watching for updates on the company's Matrix-M adjuvant platform for potential beyond infectious diseases, while high short interest fuels discussions of a potential squeeze. Despite this positive momentum, many on the forums remain skeptical about current management's ability to capitalize on these opportunities.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings (RCAT) is surging after reporting preliminary Q4 revenue results indicating massive year-over-year growth, sparking widespread excitement. The community is buzzing with talk of a potential short squeeze, driven by strong belief in its U.S.-made defense drone technology and anticipation of new details from an upcoming industry conference. This positions RCAT at the forefront of the accelerating demand within the defense and drone sectors.

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. It currently advancing its Bria-IMT™ targeted immunotherapy in combination with an immune check point inhibitor in a pivotal 1 Phase 3 study in metastatic breast cancer. The company was founded by Charles L. Wiseman and Isaac Benjamin Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

BriaCell Therapeutics Corp - Ordinary Shares - New

BriaCell Therapeutics Corp

BriaCell Therapeutics (BCTX) is trending due to reports of a sustained complete resolution of lung metastasis in a metastatic breast cancer patient treated with its Bria-OTS therapy, generating significant excitement about a potential breakthrough. However, community sentiment is divided, with many celebrating the "game changer" news while a skeptical portion anticipates another offering or "pump and dump" given the company's past history of frequent capital raises and stock consolidations following positive announcements.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of ZyVersa Therapeutics surged Wednesday, drawing heavy attention from retail investors after the company unveiled new plans to position its inflammasome ASC inhibitor, IC 100, as an adjunct to GLP-1 receptor agonists in addressing obesity-related cardiometabolic complications.The stock closed up&nbsp;over 24% at $0.68 on Wednesday before paring gains in after-hours trading, falling 12.38% to $0.60.In a shareholder letter, CEO Stephen C. Glover outlined a strategy to target inflammation-driven pathways that remain unaddressed by GLP-1 agonists such as semaglutide.&nbsp;While these drugs have transformed obesity treatment by inducing significant weight loss, Glover pointed to high discontinuation rates — up to 85% within two years among non-diabetic patients—and side effects including muscle loss and gastrointestinal issues as key limitations.“While GLP-1 agonists have revolutionized obesity treatment, significant unmet medical needs remain,” Glover wrote.ZyVersa’s IC 100 targets ASC and ASC specks, which play a central role in initiating and perpetuating inflammasome activation.&nbsp;Unlike most inflammasome inhibitors in development that target NLRP3, IC 100 is designed to broadly inhibit several inflammasomes implicated in obesity, insulin resistance, and diabetic nephropathy, including AIM2, NLRP1, NLRC4, and others.Preclinical studies cited by the company demonstrated that IC 100 reduced inflammation and plaque formation in an ApoE knockout model of atherosclerosis, lowered fasting blood glucose in diabetic kidney disease models, and suppressed key proinflammatory cytokines such as IL-1β, IL-18, and IL-6.ZyVersa said it will initiate a preclinical study combining IC 100 with semaglutide in H1 2025, file an Investigational New Drug (IND) application in H2 2025, and begin Phase 1 clinical trials in H1 2026 focusing on overweight individuals with cardiometabolic risk factors.Retail sentiment surged on Stocktwits, where message volume was marked “extremely high” and sentiment labeled “extremely bullish.”&nbsp;One user speculated the stock could rally to $2, while another suggested it looked “set up nicely” to retest the $1.05 pre-market high.<stembedurl>https://stocktwits.com/Netplus1/message/613838869</stembedurl><stembedurl>https://stocktwits.com/Chrismg8/message/613837620</stembedurl>Shares of Zyversa have fallen 37.2% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

One user thought Viking's stock "should be up 30-40%" as it has the "best in class oral GLP-1 now."

Retail Traders Flock To ZyVersa As IC 100 Obesity Plan Looks To Fill GLP-1 Gaps

ZyVersa's IC 100 strategy focuses on targeting inflammasome-driven inflammation to enhance weight loss and improve metabolic function in obesity patients. 

Equity

ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It develops drugs for the treatment of renal and inflammatory diseases. The company was founded by Stephen C. Glover in 2014 and is headquartered in Weston, FL.

ZyVersa Therapeutics Inc

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Current Price	$0.19
Prev Close	$0.2298
Open	$0.225
Dividend Yield	0.00%
50-Day Moving Average	$0.1448
Beta	0.13
Avg. Volume	27,309.86
PE Ratio	-0.04

52-Week High	$1.94
52-Week Low	$0.11
Market Capitalization	$1.86M
EPS (Annual)	-$8.48
Price to Book	-0.13
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

ZVSA
ZyVersa Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ZVSA News

ZVSAZyVersa Therapeutics Inc